Please cite this article as: Lees EK, Krol E, Shearer K, Mody N, Gettys TW, Delibegović M, Effects of hepatic protein tyrosine phosphatase 1B and methionine restriction on hepatic and whole-body glucose and lipid metabolism in mice, Metabolism (2014Metabolism ( ), doi: 10.1016Metabolism ( /j.metabol.2014 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Introduction
Insulin resistance and type 2 diabetes are increasing in prevalence worldwide [1] . Type 2 diabetes is preceded by insulin resistance; characterised by decreased insulin-dependent glucose uptake into peripheral tissues and inadequate suppression of hepatic glucose production, resulting in hyperglycemia [2] . Insulin secretion is initially increased to counteract this; however, type 2 diabetes occurs when the pancreatic beta cells can no longer compensate for the increased demand for insulin
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secretion due to loss of beta cell mass [3] . The mechanism(s) behind insulin resistance remain unclear [4, 5] although, it is generally agreed that impaired post-insulin receptor (IR) signal transduction is involved [6] .
Insulin signaling is activated when insulin binds to the IR, leading to autophosphorylation of the IR and the ability of it to phosphorylate target substrates including the IRS proteins [6] . Further downstream, protein kinase B (PKB/Akt) is phosphorylated to promote glucose uptake [6] . PKB/Akt also leads to the activation of the mechanistic target of rapamycin complex 1 (mTORC1), which stimulates protein synthesis through activating p70 ribosomal S6 kinase (p70S6K) and its downstream target; ribosomal protein S6 (S6) [6] . Insulin resistance is also linked to the accumulation of hepatic lipids [2] , as occurs in non-alcoholic fatty liver disease (NAFLD). NAFLD, which affects 20-35% of the population, is characterised by excess lipid stores within the liver in the absence of alcohol consumption [7] .
Methionine restriction (MR) is a dietary modification that involves reducing the amount of the essential amino acid, methionine, to 5-times lower levels than the control diet (0.86% to 0.172%). In comparison to control-fed rodents, MR limits weight gain and diminishes accretion of adiposity, despite increased food intake [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] due to stimulation of nonshivering thermogenesis in adipose tissue, leading to elevated energy expenditure [10, 16] . It also improves whole-body glucose homeostasis [8, 11, 12, 17] and insulin signaling in peripheral tissues [11, 17] .The enhancement of insulin signaling in the liver by MR is a direct effect of secondarily limiting the availability of the cysteine needed for synthesis of hepatic glutathione (GSH) [17] [18] [19] . GSH is an essential co-factor for GSH peroxidase which activates phosphatase and tensin homologue (PTEN) [20] a phosphatase responsible for the dephosphorylation of phosphatidylinositol (3,4,5)-trisphosphate (PIP 3 ) [6] . The reduction in hepatic glutathione by MR slows the reactivation of PTEN, which increases PIP 3 levels and amplifies downstream PKB/Akt phosphorylation [17] . As MR targets PIP 3 , it has no effect on upstream components such as levels of IR or IRS1 phosphorylation [17] . MR also decreases hepatic lipogenesis through targeted effects on lipogenic gene expression, leading to decreased hepatic triglyceride levels [8, 11, 14, 21, 22] . For example, a 16-week MR intervention in human subjects with metabolic syndrome produced a significant reduction in hepatic lipid content [23] .
Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously expressed non-receptor tyrosine phosphatase which negatively regulates leptin and insulin signaling [2, [24] [25] [26] [27] . Due to PTP1B downregulating these signaling pathways, whole-body Ptp1b knockout mice are lean with enhanced insulin sensitivity [28, 29] . Within the insulin signaling pathway PTP1B directly targets the IR and IRS1 in muscle and liver, whereas it is not a negative regulator of these proteins in adipose tissue [2, 27, 30] . Liver-specific knockout of Ptp1b from birth results in improved glucose homeostasis caused by enhanced hepatic insulin signaling [2] and tamoxifen-inducible hepatic Ptp1b knockdown in adult A C C E P T E D M A N U S C R I P T
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mice leads to the reversal of high-fat diet-induced glucose intolerance [31] . Hepatic PTP1B inhibition also lowers hepatic triacylglycerol storage [31] and lipogenic gene expression [2] . Pharmaceutical companies have been developing PTP1B inhibitors as insulin-sensitizers, and currently the inhibitor trodusquemine is in phase 2 clinical trials [32] . Furthermore, an antisense oligonucleotide targeting PTP1B, developed by ISIS Pharmaceuticals also improved insulin sensitivity in monkeys [33] .
Due to hepatic PTP1B directly targeting IR and IRS1 within the insulin signaling pathway and MR acting downstream to amplify PKB/Akt phosphorylation; the aim of this study was to determine if there was a synergistic effect of a dual-therapy on hepatic insulin signaling and whole-body glucose homeostasis.
Materials and Methods

Ethics statement
All animal studies were approved by the University of Aberdeen Ethics Review Board and completed under a project licence (PPL60/3951) approved by the UK Home Office under the Animals (Scientific Procedures) Act 1986.
Animals
Albumin-Cre mice are crossed with Ptp1b fl/fl mice resulting in Alb-Ptp1b -/-mice with hepatocytespecific deletion of PTP1B from birth. Alb-Ptp1b -/-and Ptp1b fl/fl mice were previously described [2] .
Female (5-7 mo old) and male (9-12 mo old) mice studied were on a mixed 129Sv/C57BL6
background. Mice were individually caged and maintained on a 12h-h light/dark cycle at 22-24 °C with free access to food and water. Mice were maintained on a control diet (0.86% methionine) (Dyets, Bethlehem, PA, USA) for 2 weeks. After randomising for body weight, half (females; n=8, males; n=5) of the control Ptp1b fl/fl mice were placed on control diet and half (females; n=8, males; n=5) on to MR diet (0.172% methionine) (Dyets, Bethlehem, PA, USA). All Alb-Ptp1b -/-mice were placed on MR diet. Glutamic acid content of the MR diet was adjusted to produce equal amounts of total amino acids in both diets. Body weight and food intake were recorded every 3 days. After 8 weeks on the diet, the mice were fasted for 5-hours before being i.p. injected with saline or insulin (females 0.8mU/g body weight, males 10mU/g body weight). Cervical dislocation was performed 10 minutes post-injection and tissues were immediately frozen in liquid nitrogen.
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PTP1B activity assay
PTP1B activity was measured as described previously [31] . Briefly, liver lysates were prepared in PTP lysis buffer (130 mmol/l NaCl, 20 mmol/l TRIS (pH 7.5), 5 mmol/l EDTA, 1% Triton X-100 (v/v), 0.5% Nonidet P-40 (v/v)-containing protease inhibitors). PTP1B protein was immunoprecipitated using PTP1B antibody (Millipore, Watford, UK) and protein G-sepharose beads.
The reaction was performed using pp60 c-src C-terminal phosphoregulatory peptide (Enzo Life Sciences, Exeter, UK) for 30 minutes at 30°C with constant shaking. The amount of phosphate produced was measured by absorbance at 620 nm and used to indicate level of PTP1B protein activity.
Immunoblotting
Frozen liver lysates were prepared in RIPA buffer as described previously [27] . 
Serum analysis
Six-weeks after beginning MR or control diet, tail vein blood samples were taken following a 5-h fast.
All serum measurements were made on these. Serum glucose (glucose oxidase, Thermo Scientific, Waltham, MA, USA) and serum triacylglycerol (Sentinel Diagnostics, Milan, Italy) were measured using appropriate kits. Serum insulin and leptin (CrystalChem, Downers Grove, IL, USA) were determined by ELISA. Serum NEFAs were measured using a kit (Wako Chemicals, Richmond, VA, USA). Assays were measured using a Spectramax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
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Glucose and pyruvate tolerance tests
Glucose tolerance tests were performed after 5-weeks of dietary treatment. Mice were i.p. injected, following a 5-h fast, with 2 mg/g BW glucose. For pyruvate tolerance tests, performed after 7-weeks of dietary treatment, mice were injected with 2 mg/g pyruvate. Tail blood glucose measurements using glucometers (AlphaTRAK, Berkshire, UK) were taken immediately before and at 15, 30, 60 and 120 min post-injection.
Gene expression analysis
Total RNA was isolated from mouse liver using peqGOLD TriFast (Peqlab, Sarisbury Green, UK).
First strand cDNA was synthesized from 1 µg of total RNA using bioscript cDNA synthesis kit (Bioline, London, UK), oligo (dT) 18 primers and random hexamer primers. Quantitative PCR (qPCR) was used to amplify target genes using GoTaq qPCR Master Mix (Promega, Southampton, UK) and gene-specific primers on the Roche LightCycler® 480 System (Roche Diagnostics, Burgess
Hill, UK). Relative gene expression was calculated using the Pfaffl method [34] and normalised to the reference gene hypoxanthine-guanine phosphoribosyltransferase (Hprt).
Data analysis
Data are expressed as mean ± SEM. Statistical analyses were performed using repeated measures two-way ANOVA with Bonferroni multiple comparison post-tests or one-way ANOVA with Tukey's multiple comparison post-tests, as appropriate. P < 0.05 was considered statistically significant.
GraphPad Prism 5 statistical software (GraphPad Software, Inc., San Diego, CA, USA) was used for analyses.
Results
MR does not affect hepatic PTP1B protein or activity levels
To be able to assess if any further improvements in glucose or lipid homeostasis occur when adding hepatic PTP1B inhibition to MR, it was first important to ensure that MR was not affecting hepatic PTP1B or activity levels. Hepatic PTP1B protein levels were significantly decreased by 32% in female MR-fed Alb-Ptp1b -/-mice relative to female MR-fed Ptp1b fl/fl mice ( Fig. 1A and B ). Hepatic PTP1B protein activity was also decreased by 40% in female MR-fed Alb-Ptp1b -/-mice compared to
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
female MR-fed Ptp1b fl/fl mice (Fig. 1C) . MR diet in Ptp1b fl/fl female mice had no effect on hepatic PTP1B protein or activity levels, compared to control-fed Ptp1b fl/fl mice (Fig. 1A , B and C).
MR decreases body weight in both Alb-Ptp1b
-/-and Ptp1b fl/fl mice.
Both female and male mice on MR (Ptp1b fl/fl and Alb-Ptp1b
-/-) exhibited decreased body weight throughout the course of the study compared to control-fed Ptp1b fl/fl mice ( Fig. 2A and B) . Female MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-mice had significantly lower body weight relative to control-fed Ptp1b fl/fl mice from days 22-43 of the dietary treatment ( Fig. 2A) . MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-mice did not differ in body weight levels throughout the duration of the study in both female and male mice ( Fig. 2A and B) . Food intake (g/ g BW/ day) was significantly increased in female and male MR-fed Alb-Ptp1b -/-mice and also elevated in MR-fed Ptp1b fl/fl mice compared to control-fed Ptp1b fl/fl mice ( Fig. 2C and D) There were no differences in food intake in either female or male groups between MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-mice ( Fig. 2C and D) .
MR and hepatic PTP1B knockdown increase hepatic insulin signaling but do not act synergistically.
MR alone had no effect on levels of phosphorylation of the IR (MR-fed Ptp1b fl/fl vs. control-fed There were no differences for diet or genotype on levels of phosphorylated or total S6 (Fig. 3A, B and E). (Fig. 4B ).
To examine if there was any additional effect of supplementing MR with hepatic PTP1B knockdown on suppression of hepatic gluconeogenesis, we performed a pyruvate-tolerance test (PTT) in female mice (Fig. 4C) . MR-fed Alb-Ptp1b -/-mice significantly improved and MR-fed Ptp1b fl/fl mice also enhanced their response to a pyruvate challenge compared to control-fed Ptp1b fl/fl mice; however, there were no additional differences between MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-mice (Fig.   4C ). Both MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-female mice had significantly decreased fasting blood glucose levels relative to control-fed Ptp1b fl/fl mice (Fig. 4D ). There were no additive differences between MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-mice in fasting blood glucose levels (Fig. 4D) . In male mice, there were no differences between groups on fasting blood glucose levels (Fig. 4E) . In both female and male mice both groups fed MR (Ptp1b fl/fl and Alb-Ptp1b
significantly lower fasting serum insulin levels relative to control-fed Ptp1b fl/fl mice ( Fig. 4F and G).
Again, there was no difference between MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-mice for fasting serum insulin levels in either female or male mice ( Fig. 4F and G) .
MR improves lipid homeostasis which is not further exacerbated by hepatic PTP1B knockdown
Both MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-female mice had significantly decreased fasting serum leptin levels relative to control-fed Ptp1b fl/fl mice (Fig. 5A) . However, there were no additional differences between MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-mice in fasting serum leptin levels in female mice (Fig. 5A) . In male mice, both MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-mice had lower fasting serum leptin levels compared to control-fed Ptp1b fl/fl mice; yet again these were not additive (Fig. 5B ). Diet and genotype had no effect on fasting serum NEFA levels or fasting serum triacylglycerol levels in either female or male mice (Fig. 5C , D, E and F). In female mice, both MRfed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-mice had significantly decreased hepatic gene expression of Srebp1c and also decreased expression of other lipogenic genes, including Srebp1a and Fas relative to control-fed Ptp1b fl/fl mice (Fig. 5G ). There were no differences in levels of these hepatic lipogenic genes between MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-female mice (Fig. 5G ). Both female MR-fed ) did not differ from each other (Fig. 5G) .
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Discussion
The increasing prevalence of metabolic syndrome demands more effective drug therapies [35] . MR produces many beneficial effects including reduced body mass and adiposity and improved glucose homeostasis [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . We have shown previously that both hepatic PTP1B deletion from birth or knockdown in adult insulin-resistance mice protects against the development of insulin resistance and reverses established glucose intolerance, respectively [2, 31, 36] . These studies established definitively that in the liver, PTP1B deletion results in increased IR and IRS1 phosphorylation. Recent studies on the beneficial insulin sensitizing effects of MR diet in the liver revealed that hepatic PKB/Akt phosphorylation is enhanced [11, 17] . We therefore hypothesised that there could be an additive effect on hepatic insulin sensitivity and whole-body glucose homeostasis if MR diet is combined with liver PTP1B deficiency. Our study suggests that MR improves glucose homeostasis and lipid metabolism; however, there were no major additional therapeutic effects of the combined treatment.
Hepatic PTP1B protein levels and PTP1B enzyme activity levels in female mice were decreased as expected in the Alb-Ptp1b -/-mice. The MR-fed Alb-Ptp1b -/-mice did not present a complete deletion of PTP1B within the liver as it has in other studies [2] , but rather a 32% decrease in protein and 40% decrease in activity levels; however, the deletion is hepatocyte-specific and so there are other cell types expressing normal levels of PTP1B within the whole liver lysates used for these assays [2] . The level of deletion would be consistent with the physiological level of PTP1B inhibition expected to be achieved by inhibitor drugs and therefore the results represent applicable findings [37] . It was recently reported that MR limits the activity of hepatic phosphatase PTEN, and the authors found no evidence to suggest that PTP1B was a target of the diet [17] . Thus, it is important that we found that MR itself had no effect on hepatic levels of PTP1B protein or activity so that we could directly assess the utility of a combined treatment.
MR causes a decrease in body weight despite elevating food intake [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] ; however, hepatic PTP1B deletion has no affect on energy balance [2, 31] . The body weight loss and increased food intake produced by MR compared to control-fed mice was similar between genotypes and is therefore likely to be an effect of MR only. The study also found that MR can decrease body weight and enhance energy intake in mice on a new genetic background (129Sv/C57BL6), confirming findings from other genetic backgrounds [8, 11, 13, 16, 17] .
In agreement with previous findings, which demonstrated that hepatic PTP1B directly targets the IR and IRS1 [2] , Alb-Ptp1b -/-mice had increased levels of phosphorylation of the IR compared to Ptp1b fl/fl mice. MR itself caused no change in phosphorylation levels of hepatic IR, consistent with recent findings which demonstrated that MR limits degradation of PIP 3 , leading to enhanced downstream activation and phosphorylation of PKB/Akt, which we also found in this study [17] . It
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was hypothesised that hepatic PTP1B inhibition in combination with MR would act additionally on phosphorylation of PKB/Akt; however, this was similar between the combined treatment and MR alone. It may be that MR-treatment alone already leads to maximally increased PKB/Akt phosphorylation so that increased signaling upstream of PKB/Akt at the level of IR/IRS1 (achieved by PTP1B inhibition) cannot lead to further improvements. This may suggest that this is the major mode of action that MR plays in the liver.
Consistent with MR's known effects to improve glucose homeostasis, MR in both groups improved glucose tolerance and lowered blood glucose and serum insulin levels compared to control-fed Ptp1b fl/fl mice [8, 9, 11, 12, 17] . This was further improved by PTP1B knockdown in a glucose tolerance test in female mice; however, there was no additional effect present in the male mice. The reason behind the additional improvements in glucose tolerance in female mice that were not present in male mice could be due to the male mice being older and therefore naturally more glucose intolerant compared to the females [38] . Furthermore, we cannot exclude the possibility that sex hormones such as estrogen play an additional beneficial and protective role in the MR-fed Alb-Ptp1b
. Blood glucose levels in a pyruvate tolerance test and fasting blood glucose and serum insulin levels were similarly lowered between female MR-fed Ptp1b fl/fl and MR-fed Alb-Ptp1b -/-mice.
There was also no further improvement by inhibition of hepatic-PTP1B in the male mice. Since the combined-treatment of MR and hepatic PTP1B inhibition did not result in additional enhancement in hepatic insulin signaling, or suppression of blood glucose, serum insulin and hepatic gluconeogenic genes, this suggests that MR alone is sufficient to observe these beneficial effects.
Interestingly, the combined MR and hepatic PTP1B inhibition treatment produced no further improvements in lipid metabolism to MR alone, with fasting serum leptin levels being the same between the MR-fed groups, but both lower than Ptp1b fl/fl control-fed mice. Due to no additional effect of hepatic PTP1B knockdown this finding is most likely due to MR decreasing adiposity levels [8] [9] [10] [11] [12] [14] [15] [16] . MR decreases hepatic lipogenesis [9-11, 14, 21, 40] and hepatic PTP1B deletion has also been shown to produce similar findings [2] ; but again, supplementing MR with hepatic PTP1B inhibition led to no further effects on hepatic lipogenesis. This could be due to MR inhibiting lipogenic gene expression by such a substantial amount that hepatic PTP1B inhibition cannot decrease gene expression further, or it is possible that there is a common mechanism behind these two treatments. Both MR-fed groups expressed decreased hepatic gluconeogenesis compared to controlfed Ptp1b fl/fl mice, although adding hepatic PTP1B inhibition to MR led to no further reduction. This corresponds with the same level of insulin-stimulated PKB/Akt activation in both MR-fed groups, as gluconeogenesis is down-regulated downstream of PKB/Akt [6] . MR was shown in a recent study to inhibit hepatic gluconeogenesis [11] and hepatic PTP1B knockdown also decreases hepatic gluconeogenic gene expression [2, 31] . 
